The selection and evaluation of new chelating agents for the treatment of iron overload

Area of Science:

• Pharmacology
• Biochemistry
• Toxicology

Background:

• Hemosiderosis, characterized by iron overload, necessitates effective iron chelator therapy.
• Deferrioxamine B is a standard treatment, but its efficacy and administration route can be limiting.

Purpose of the Study:

• To systematically evaluate a wide range of iron chelating compounds for potential therapeutic use in hemosiderosis.
• To identify novel chelators with improved efficacy and oral bioavailability compared to existing treatments.

Main Methods:

• A hypertransfused mouse model was employed to assess iron depletion and excretion.
• Over 70 iron chelators, including hydroxamic acids, phenols, catechols, and tropolones, were screened.
• Iron levels in urine, spleen, and liver were quantified using atomic absorption spectroscopy.

Main Results:

• Ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid) demonstrated superior iron-chelating efficacy compared to deferrioxamine B.
• This novel compound exhibited significant oral activity, offering a potential advantage over parenteral administration.
• The study identified key factors influencing the therapeutic effectiveness of iron chelating agents.

Conclusions:

• Ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid) represents a promising candidate for hemosiderosis treatment due to its enhanced efficacy and oral bioavailability.
• This systematic screening provides valuable insights into the development of improved iron chelator therapies.
• Further investigation into the optimal use of this compound is warranted.